CO5280211A1 - Forma de cristal de eplerenona que exhibe mejorada rata de disolucion - Google Patents

Forma de cristal de eplerenona que exhibe mejorada rata de disolucion

Info

Publication number
CO5280211A1
CO5280211A1 CO00094075A CO00094075A CO5280211A1 CO 5280211 A1 CO5280211 A1 CO 5280211A1 CO 00094075 A CO00094075 A CO 00094075A CO 00094075 A CO00094075 A CO 00094075A CO 5280211 A1 CO5280211 A1 CO 5280211A1
Authority
CO
Colombia
Prior art keywords
eplerenone
crystalline
rat
crystal form
exhibiting improved
Prior art date
Application number
CO00094075A
Other languages
English (en)
Spanish (es)
Inventor
P Barton Kathleen
Thomas B Borehardt
V Carlos Marlon
Desai Subhash
Leonard J Ferro
Henry T Gaud
Scott Ganser
Clay R Little
S Mudipalli Partha
Mark A Pietz
Daniel R Pilipauskas
L Sing Yuen-Lung
Glen L Stahl
Joseph J Wieczoreck
Y Chris Yan
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5280211A1 publication Critical patent/CO5280211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CO00094075A 1999-12-08 2000-12-11 Forma de cristal de eplerenona que exhibe mejorada rata de disolucion CO5280211A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16960899P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08

Publications (1)

Publication Number Publication Date
CO5280211A1 true CO5280211A1 (es) 2003-05-30

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00094075A CO5280211A1 (es) 1999-12-08 2000-12-11 Forma de cristal de eplerenona que exhibe mejorada rata de disolucion

Country Status (18)

Country Link
EP (1) EP1177204A2 (fr)
JP (1) JP2003516414A (fr)
KR (1) KR100607923B1 (fr)
CN (2) CN1557833A (fr)
AU (1) AU784946B2 (fr)
BR (1) BR0008057A (fr)
CA (1) CA2362669A1 (fr)
CO (1) CO5280211A1 (fr)
EA (1) EA007934B1 (fr)
HK (1) HK1050536A1 (fr)
HU (1) HUP0203032A3 (fr)
IL (3) IL144764A0 (fr)
MX (1) MXPA01008056A (fr)
MY (1) MY131878A (fr)
NO (1) NO20013856L (fr)
NZ (2) NZ513961A (fr)
PE (1) PE20010917A1 (fr)
WO (1) WO2001042272A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080181A2 (fr) * 2002-03-20 2003-10-02 Pharmacia Corporation Formulation de l'eplerenone stable au stockage
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (fr) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Procede ameliore permettant la preparation et la purification de l'eplerenone
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
EP2582365B1 (fr) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pour stimuler la réépithélialisation durant la cicatrisation d'une blessure
EP3362095B1 (fr) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et préparations pharmaceutiques pour le traitement de la neovascularisation choroidienne
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (fr) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement de la rosacée oculaire
WO2023204729A1 (fr) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Composition pharmaceutique à base d'une nouvelle substance acide 4-[2-(1н-imidazol-4-yl)-éthylcarbamoyl]-butanol et procédé de production de la substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
JP2001509792A (ja) * 1996-12-11 2001-07-24 ジー．ディー．サール アンド カンパニー ９，１１−エポキシステロイドの製造法ならびに該方法に有用な中間体
EA004064B1 (ru) * 1999-03-05 2003-12-25 Джи.Ди.Сирл Ллс Комбинированная терапия ингибитором ангиотензинпревращающего фермента и эпоксистероидным антагонистом альдостерона для лечения сердечно-сосудистого заболевания

Also Published As

Publication number Publication date
IL176511A (en) 2007-08-19
NZ530028A (en) 2005-08-26
EA007934B1 (ru) 2007-02-27
HUP0203032A3 (en) 2003-04-28
EP1177204A2 (fr) 2002-02-06
AU2049201A (en) 2001-06-18
KR20010112261A (ko) 2001-12-20
JP2003516414A (ja) 2003-05-13
WO2001042272A2 (fr) 2001-06-14
HK1050536A1 (en) 2003-06-27
CN1377365A (zh) 2002-10-30
IL144764A0 (en) 2002-06-30
CA2362669A1 (fr) 2001-06-14
AU784946B2 (en) 2006-08-03
NZ513961A (en) 2004-02-27
MXPA01008056A (es) 2003-07-21
KR100607923B1 (ko) 2006-08-04
NO20013856D0 (no) 2001-08-08
CN1557833A (zh) 2004-12-29
PE20010917A1 (es) 2001-09-10
WO2001042272A9 (fr) 2002-12-12
MY131878A (en) 2007-09-28
IL144764A (en) 2007-08-19
BR0008057A (pt) 2002-04-23
HUP0203032A2 (hu) 2002-12-28
CN1152886C (zh) 2004-06-09
WO2001042272A3 (fr) 2001-11-29
NO20013856L (no) 2001-10-08
EA200100871A1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
CO5280211A1 (es) Forma de cristal de eplerenona que exhibe mejorada rata de disolucion
AR022254A1 (es) Composicion de administracion oral.
GB2374302B (en) Power material for electrostatic application to a substrate and electrostatic application of the powder material to a substrate
IT9022155A0 (it) Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione
WO2005034872A3 (fr) Excipients pour administration medicamenteuse a base de materiaux a phase cristalline liquide inversee
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
WO2001041770A3 (fr) Compositions d'eplerenone nanoparticulaire
BR0116793A (pt) Produtos de hormÈnio de esteróide e métodos para prepará-los
AU2003221604A8 (en) Use of an active substance that binds to cd28 for producing a pharmaceutical composition
HUP0600593A3 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents and pharmaceutical compositions thereof
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
CO5770095A1 (es) Forma cristalina gamma-d del clorhitrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
HK1053601A1 (en) Pharmaceutical composition for the controlled release of paracetamol
HUP0203060A3 (en) Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same
AU7405000A (en) Melt granulated composition and modified release dosage form prepared from said composition
IL139512A0 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates
GB0204772D0 (en) Pharmaceutical dosage forms
DE69813872D1 (de) Komplex aus carrageenan und einem wasserlöslichen medikament mit einer spezifischen granulometrie und entsprechende pharmazeutische zusammensetzungen mit gesteuerter freisetzung
HUP0104009A3 (en) New crystal modification of torasemide, process for its preparation, its use as a ran material and pharmaceutical compositions containing it
AU4170299A (en) Composition for the transdermal administration of non-steroidal anti-inflammatory drugs
HUP9903747A3 (en) New process for the preparation of mometasone furoate
PE20010918A1 (es) Forma cristalina de eplerenona
CO5380034A1 (es) Forma cristalina de eplerenona
AU5859799A (en) Pharmaceutical composition containing calcium valproate with delayed active substance release and method for the production of said composition

Legal Events

Date Code Title Description
FC Application refused